PLASMA p-tau217 AS A MINIMALLY INVASIVE BIOMARKER FOR ALZHEIMER’S DISEASE DIAGNOSIS: ANALYTICAL PLATFORMS, DIAGNOSTIC PERFORMANCE, AND CLINICAL IMPLEMENTATION CHALLENGES
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6492Keywords:
Alzheimer’s Disease; Plasma p-tau217; Biomarkers; Analytical Platforms; Clinical ImplementationAbstract
Background: Plasma phosphorylated tau at threonine 217 (p-tau217) has emerged as a promising minimally invasive biomarker for the biological detection of Alzheimer’s disease. This review aimed to evaluate the analytical platforms used for plasma p-tau217 measurement, their diagnostic performance, and the principal challenges associated with its implementation in clinical practice.
Methods: A structured narrative review of publications issued between 2019 and 2026 was conducted using PubMed/MEDLINE, Scopus, and Web of Science, with Google Scholar and reference-list screening used as supplementary sources. Studies evaluating plasma p-tau217 assays, analytical validation, diagnostic accuracy, comparison with positron emission tomography or cerebrospinal fluid biomarkers, and clinical implementation were included. Owing to substantial methodological and analytical heterogeneity, findings were synthesised narratively.
Results: Plasma p-tau217 showed high diagnostic performance for identifying amyloid and tau pathology and generally outperformed other phosphorylated tau isoforms. Mass-spectrometry-based measurement, particularly percentage p-tau217, demonstrated the highest analytical selectivity and diagnostic accuracy. However, fully automated immunoassays showed greater potential for routine laboratory use because of their higher throughput and reduced technical complexity. Diagnostic performance varied according to the assay, cut-off values, clinical setting, disease prevalence, and patient characteristics. A two-cut-off strategy improved classification while retaining an intermediate group requiring confirmatory testing.
Conclusions: Plasma p-tau217 may substantially improve access to biological Alzheimer’s disease diagnostics, but it should not be interpreted as a stand-alone test. Clinical implementation requires assay-specific validation, standardization, external quality control, and integration with clinical assessment and confirmatory diagnostic methods.
References
Alzheimer’s Association. (2021). Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 17(3). https://doi.org/10.1002/alz.12328
Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E. M., Langhough, R., Cody, K. A., Wilson, R. E., Carlsson, C. M., Vanmechelen, E., Montoliu-Gaya, L., Lantero-Rodriguez, J., Rahmouni, N., Tissot, C., Stevenson, J., Servaes, S., Therriault, J., Pascoal, T. A., … Zetterberg, H. (2024). Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurology, 81(3). https://doi.org/10.1001/jamaneurol.2023.5319
Ashton, N. J., Keshavan, A., Brum, W. S., Andreasson, U., Arslan, B., Droescher, M., Barghorn, S., Vanbrabant, J., Lambrechts, C., Van Loo, M., Stoops, E., Iyengar, S., Ji, H., Xu, X., Forrest-Hay, A., Zhang, B., Luo, Y., Jeromin, A., Vandijck, M., … Zetterberg, H. (2025). The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau round robin study. Alzheimer’s & Dementia, 21(2). https://doi.org/10.1002/alz.14508
Atri, A., Dickerson, B. C., Clevenger, C., Karlawish, J., Knopman, D., Lin, P. J., Norman, M., Onyike, C., Sano, M., Scanland, S., & Carrillo, M. (2024a). Alzheimer’s Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer’s disease and related disorders (DETeCD-ADRD): Executive summary of recommendations for primary care. Alzheimer’s & Dementia, 21(6). https://doi.org/10.1002/alz.14333
Bali, D., Hansson, O., & Janelidze, S. (2024). Effects of certain pre-analytical factors on the performance of plasma phospho-tau217. Alzheimer’s Research & Therapy, 16(1). https://doi.org/10.1186/s13195-024-01391-1
Barthélemy, N. R., Salvadó, G., Schindler, S., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., Li, Y., La Joie, R., Benzinger, T. L. S., Morris, J. C., Mattsson-Carlgren, N., Palmqvist, S., Ossenkoppele, R., Rabinovici, G. D., Stomrud, E., … Hansson, O. (2024). Highly accurate blood test for Alzheimer’s disease comparable or superior to clinical CSF tests. Nature Medicine, 30, 1–1. https://doi.org/10.1038/s41591-024-02869-z
Chapleau, M., Iaccarino, L., Soleimani-Meigooni, D., & Rabinovici, G. D. (2022). The role of amyloid PET in imaging neurodegenerative disorders: A review. Journal of Nuclear Medicine, 63(Supplement 1), 13S–19S. https://doi.org/10.2967/jnumed.121.263195
Frisoni, G. B., Festari, C., Massa, F., Cotta Ramusino, M., Orini, S., Aarsland, D., Agosta, F., Babiloni, C., Borroni, B., Cappa, S. F., Frederiksen, K. S., Froelich, L., Garibotto, V., Haliassos, A., Jessen, F., Kamondi, A., Kessels, R. P., Morbelli, S. D., O’Brien, J. T., … Nobili, F. (2024). European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. The Lancet Neurology, 23(3), 302–312. https://doi.org/10.1016/S1474-4422(23)00447-7
GBD 2019 Dementia Forecasting Collaborators. (2022). Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: An analysis for the Global Burden of Disease Study 2019. The Lancet Public Health, 7(2). https://doi.org/10.1016/S2468-2667(21)00249-8
Hall, S., Janelidze, S., Londos, E., Leuzy, A., Stomrud, E., Dage, J. L., & Hansson, O. (2020). Plasma phospho-tau identifies Alzheimer’s co-pathology in patients with Lewy body disease. Movement Disorders, 36(3), 767–771. https://doi.org/10.1002/mds.28370
Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Le Bastard, N., Molinuevo, J. L., Nisenbaum, L. K., Rutz, S., Salamone, S. J., Teunissen, C. E., Traynham, C., Umek, R. M., Vanderstichele, H., Vandijck, M., … Blennow, K. (2021). The Alzheimer’s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. Alzheimer’s & Dementia, 17(9), 1575–1582. https://doi.org/10.1002/alz.12316
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., Molinuevo, J. L., Okonkwo, O. C., Pani, L., Rafii, M. S., Scheltens, P., Siemers, E., Snyder, H. M., Sperling, R., Teunissen, C. E., & Carrillo, M. C. (2024). Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia, 20(8). https://doi.org/10.1002/alz.13859
Janelidze, S., Barthélemy, N. R., He, Y., Bateman, R. J., & Hansson, O. (2023). Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2023.0199
Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., Triana-Baltzer, G., Theunis, C., Slemmon, R., Mercken, M., Kolb, H., Dage, J. L., & Hansson, O. (2020). Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nature Communications, 11(1), 1683. https://doi.org/10.1038/s41467-020-15436-0
Kivisäkk, P., Fatima, H. A., Cahoon, D. S., Otieno, B., Chacko, L., Minooei, F., Demos, C., Stengelin, M., Sigal, G., Wohlstadter, J., & Arnold, S. E. (2024). Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer’s disease. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-51334-x
Kivisäkk, P., Fatima, H., Wu, C.-Y., Padmanabhan, N., Romero, D., Gorham, T., Weik, M., Dodge, H. H., Scherzer, C. R., Das, S., Chibnik, L. B., Blacker, D. L., Gomez-Isla, T., Oakley, D. H., Frosch, M. P., Hyman, B. T., Demos, C., Sigal, G., Wohlstadter, J. N., … Arnold, S. E. (2026). Postmortem associations between Alzheimer disease pathology and plasma pTau217, GFAP, and NfL in AD and AD-related dementias. Neurology, 106(4). https://doi.org/10.1212/WNL.0000000000214351
Kurz, C., Stöckl, L., Schrurs, I., Suridjan, I., Gürsel, S. Ü., Bittner, T., Jethwa, A., & Perneczky, R. (2023). Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer’s disease. Journal of Neurochemistry, 165(1), 95–105. https://doi.org/10.1111/jnc.15757
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., La Joie, R., Rabinovici, G. D., Franzmeier, N., Johnson, K., Barkhof, F., Shaw, L. M., Arkhipenko, A., Schindler, S. E., Honig, L. S., Rial, A. M., Schöll, M., Zetterberg, H., Blennow, K., Hansson, O., & Farrar, G. (2025). Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer’s disease. Alzheimer’s & Dementia, 21(3). https://doi.org/10.1002/alz.14528
Long, J. M., & Holtzman, D. M. (2019). Alzheimer disease: An update on pathobiology and treatment strategies. Cell, 179(2), 312–339. https://doi.org/10.1016/j.cell.2019.09.001
Maschio, C., & Ni, R. (2022). Amyloid and tau positron emission tomography imaging in Alzheimer’s disease and other tauopathies. Frontiers in Aging Neuroscience, 14. https://doi.org/10.3389/fnagi.2022.838034
Mattsson-Carlgren, N., Janelidze, S., Palmqvist, S., Cullen, N., Svenningsson, A. L., Strandberg, O., Mengel, D., Walsh, D. M., Stomrud, E., Dage, J. L., & Hansson, O. (2020). Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease. Brain, 143(11), 3234–3241. https://doi.org/10.1093/brain/awaa286
Montoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Karikari, T. K., Triana-Baltzer, G., Qu, Y., Theunis, C., Hirtz, C., Lehmann, S., Blennow, K., Zetterberg, H., & Pascoal, T. A. (2023). Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nature Aging, 3, 661–669. https://doi.org/10.1038/s43587-023-00405-1
Pahlke, S., Kahale, L. A., Mahinrad, S., Sousa-Pinto, B., Vieira, R. J., McAteer, M. B., Claessen, T., Contador, J., Hofmann, A., Kuchenbecker, L. A., Machado, L. S., Warmenhoven, N., Yakoub, Y., Palmqvist, S., Schindler, S. E., Teunissen, C., Whitson, H. E., Zetterberg, H., Edelmayer, R., & Tampi, M. P. (2025). Blood-based biomarkers for detecting Alzheimer’s disease pathology in cognitively impaired individuals within specialized care settings: A systematic review and meta-analysis. Alzheimer’s & Dementia, 21(11). https://doi.org/10.1002/alz.70828
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., Mattsson-Carlgren, N., Strandberg, O., Smith, R., Villegas, A., Sepulveda-Falla, D., Chai, X., Proctor, N. K., Beach, T. G., Blennow, K., … Hansson, O. (2020). Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA, 324(8), 772–781. https://doi.org/10.1001/jama.2020.12134
Palmqvist, S., Tideman, P., Mattsson-Carlgren, N., Schindler, S. E., Smith, R., Ossenkoppele, R., Calling, S., West, T., Monane, M., Verghese, P. B., Braunstein, J. B., Blennow, K., Janelidze, S., Stomrud, E., Salvadó, G., & Hansson, O. (2024). Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA, 332(15). https://doi.org/10.1001/jama.2024.13855
Palmqvist, S., Warmenhoven, N., Anastasi, F., Pilotto, A., Janelidze, S., Tideman, P., Stomrud, E., Mattsson-Carlgren, N., Smith, R., Ossenkoppele, R., Tan, K., Dittrich, A., Skoog, I., Zetterberg, H., Quaresima, V., Tolassi, C., Höglund, K., Brugnoni, D., Puig-Pijoan, A., … Hansson, O. (2025a). Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform. Nature Medicine. https://doi.org/10.1038/s41591-025-03622-w
Palmqvist, S., Whitson, H. E., Allen, L. A., Suarez-Calvet, M., Galasko, D., Karikari, T. K., Okrahvi, H. R., Paczynski, M., Schindler, S. E., Teunissen, C. E., Zetterberg, H., Carrillo, M. C., Edelmayer, R. M., Mahinrad, S., McAteer, M. B., Kahale, L. A., Pahlke, S., & Tampi, M. P. (2025b). Alzheimer’s Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings. Alzheimer’s & Dementia, 21(7). https://doi.org/10.1002/alz.70535
Petersen, K. K., Milà-Alomà, M., Li, Y., Du, L., Xiong, C., Tosun, D., Saef, B., Saad, Z. S., Du-Cuny, L., Coomaraswamy, J., Mordashova, Y., Rubel, C. E., Meyers, E. A., Shaw, L. M., Dage, J. L., Ashton, N. J., Zetterberg, H., Ferber, K., Triana-Baltzer, G., … Schindler, S. E. (2026). Predicting onset of symptomatic Alzheimer’s disease with plasma p-tau217 clocks. Nature Medicine. https://doi.org/10.1038/s41591-026-04206-y
Shi, Q., Hou, J., Peng, X., Xu, Z., Wang, Y., & Cao, D. (2026). Magnetic resonance imaging analysis for Alzheimer’s disease diagnosis using artificial intelligence: Methods, challenges, and opportunities. Ageing Research Reviews, 113, 102943. https://doi.org/10.1016/j.arr.2025.102943
Therriault, J., Brum, W. S., Trudel, L., Macedo, A. C., Bitencourt, F. V., Martins-Pfeifer, C. C., Nakouzi, M., Pola, I., Wong, M., Kac, P. R., Real, A. P., Witherow, C., Karikari, T. K., Moscoso, A., Zimmer, E. R., Schöll, M., Pascoal, T., Benedet, A. L., Ashton, N. J., … Rosa-Neto, P. (2025). Blood phosphorylated tau for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. The Lancet Neurology, 24(9), 740–752. https://doi.org/10.1016/S1474-4422(25)00227-3
Therriault, J., Janelidze, S., Benedet, A. L., Ashton, N. J., Martínez, J. A., Gonzalez-Escalante, A., Bellaver, B., Alcolea, D., Vrillon, A., Karim, H., Mielke, M. M., Hong, C. H., Roh, H. W., Contador, J., Pijoan, A. P., Algeciras-Schimnich, A., Vemuri, P., Graff-Radford, J., Lowe, V. J., … Rosa-Neto, P. (2024). Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability. Nature Aging, 4(11), 1529–1537. https://doi.org/10.1038/s43587-024-00731-y
Thijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., VandeVrede, L., Proctor, N. K., Lago, A. L., Baker, S., Sivasankaran, R., Kieloch, A., Kinhikar, A., Yu, L., Valentin, M.-A., … Boxer, A. L. (2021). Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study. The Lancet Neurology, 20(9), 739–752. https://doi.org/10.1016/S1474-4422(21)00214-3
van Harten, A. C., Wiste, H. J., Weigand, S. D., Mielke, M. M., Kremers, W. K., Eichenlaub, U., Dyer, R. B., Algeciras-Schimnich, A., Knopman, D. S., Jack, C. R., & Petersen, R. C. (2022). Detection of Alzheimer’s disease amyloid beta 1-42, p-tau, and t-tau assays. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 18(4), 635–644. https://doi.org/10.1002/alz.12406
Warmenhoven, N., Salvadó, G., Janelidze, S., Tideman, P., Mattsson-Carlgren, N., Stomrud, E., Smith, R., Ashton, N. J., Blennow, K., Zetterberg, H., Hansson, O., & Palmqvist, S. (2025). A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain, 148(2), 416–431. https://doi.org/10.1093/brain/awae346
Yun, J., Lee, J., Shin, D., Lee, E. H., Kim, J. P., Ham, H., Gu, Y., Chun, M. Y., Kang, S. H., Kim, H. J., Na, D. L., Kim, K. W., Kim, S. E., Kim, Y., Kim, J., Jung, N.-Y., Kim, Y. J., Cho, S. H., Lee, J. S., … Kim, B. (2026). Plasma phosphorylated tau 217 cutoffs for amyloid pathology and kidney function, body mass index, and anemia. JAMA Neurology, 83(3), 269. https://doi.org/10.1001/jamaneurol.2025.5530
Zetterberg, H., & Blennow, K. (2021). Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics. Molecular Neurodegeneration, 16(1). https://doi.org/10.1186/s13024-021-00430-x
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Oliwia Lenkiewicz, Julia Lenkiewicz, Zuzanna Chmielewska, Marcin Trzciński, Agata Kotłowska, Wiktoria Napiórkowska, Aleksandra Izabela Masłowska, Anna Gwóźdź-Broczkowska, Gabriela Luba
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
